AnaptysBio Inc (ANAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AnaptysBio Inc (ANAB) has a cash flow conversion efficiency ratio of -2.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.92 Million) by net assets ($12.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AnaptysBio Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
AnaptysBio Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how AnaptysBio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AnaptysBio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AnaptysBio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Turning Point Brands Inc
NYSE:TPB
|
-0.058x |
|
Serena Energia S.A.
SA:SRNA3
|
-0.007x |
|
Bio-Rad Laboratories Inc
NYSE:BIO-B
|
0.016x |
|
Swan Energy Limited
NSE:SWANENERGY
|
-0.037x |
|
Metrovacesa SA
MC:MVC
|
-0.022x |
|
Fila Holdings Corp
KO:081660
|
0.099x |
|
Ingersoll Rand (India) Limited
NSE:INGERRAND
|
0.185x |
|
Shenzhen Gongjin Electn
SHG:603118
|
-0.028x |
Annual Cash Flow Conversion Efficiency for AnaptysBio Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of AnaptysBio Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see ANAB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $37.21 Million | $19.70 Million | 0.529x | +127.72% |
| 2024-12-31 | $70.87 Million | $-135.34 Million | -1.910x | -39.28% |
| 2023-12-31 | $88.10 Million | $-120.80 Million | -1.371x | -388.33% |
| 2022-12-31 | $262.10 Million | $-73.59 Million | -0.281x | -117.94% |
| 2021-12-31 | $356.43 Million | $-45.92 Million | -0.129x | -261.04% |
| 2020-12-31 | $396.73 Million | $-14.16 Million | -0.036x | +79.21% |
| 2019-12-31 | $405.01 Million | $-69.52 Million | -0.172x | -72.11% |
| 2018-12-31 | $486.37 Million | $-48.51 Million | -0.100x | -57.81% |
| 2017-12-31 | $307.58 Million | $-19.44 Million | -0.063x | +72.52% |
| 2016-12-31 | $39.27 Million | $-9.03 Million | -0.230x | -0.69% |
| 2015-12-31 | $42.34 Million | $-9.67 Million | -0.228x | -109.37% |
| 2014-12-31 | $5.99 Million | $14.60 Million | 2.437x | +106.10% |
| 2013-12-31 | $145.00K | $-5.80 Million | -39.972x | -- |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more